Senior Pharmaceutical & Technology Executive and Current SVP, Chief
Information Officer, North America at Kyowa Kirin International plc.,
Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon’s Advisory
Vancouver, British Columbia–(Newsfile Corp. – March 3, 2021) – Entheon
Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon” or the
“Company”), a biotechnology company focused on developing psychedelic
medicines to treat addiction, is pleased to announce Nancy Maher as Special
Advisor of Data Science and Regulatory Affairs, providing expertise on the
development of the Company’s data strategy design, study design and advise on
regulatory relationships and data strategy.
Ms. Maher has served as an executive and consultant for major pharmaceutical
and information technology companies, including IBM, Gilead, Schering-Plough,
Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is currently SVP, Chief
Information Officer, North America of Kyowa Kirin International plc., and
joins Entheon as its Special Advisor of Data Science and Regulatory Affairs.
Ms. Maher will be consulting on the development and implementation of
Entheon’s data management systems for the collection, organization and
analysis of data from upcoming pre-clinical and clinical trials, partnership
initiatives, private clinic partnerships, and various technological
initiatives. In addition, Ms. Maher will inform the Company of best practices
for the design and implementation of security measures as they relate to the
Company’s data program, while also informing regulatory strategy and
relationship as it relates to advancing conversations and applications with
Health Canada, the FDA and EMA regulatory authorities.
“We would like to extend a warm welcome to Ms. Nancy Maher, who brings a
wealth of experience and industry knowledge to Entheon. Ms. Maher understands
the importance of data with regard to future product development and in
characterizing the unique variables of diagnosis and drug response in patient
populations, and we are thrilled to have access to her unique expertise,” said
Chief Executive Officer, Timothy Ko.
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to
developing and commercializing a portfolio of safe and effective
N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products”)
for the purposes of treating addiction and substance use disorders. Subject to
obtaining all requisite regulatory approvals and permits, Entheon intends to
generate revenue through the sale of its DMT Products to physicians, clinics
and licensed psychiatrists in the United States, certain countries in the
European Union and throughout Canada.
About Nancy Maher
A global IT leader with significant experience in utilizing and enabling
technology to deliver efficiency, productivity, quality and solutions for
patients and the public health sector, Nancy has an extensive background in
digital technology, big data and data analytics, as well as M&As. With more
than 20 years of industry experience, including significant leadership roles
at Gilead, Allergan, Teva, Merck, Schering-Plough, and IBM, Nancy currently
serves as Senior Vice-President, Chief Information Officer of Kyowa Kiran NA,
where she is establishing the company’s global digital and technology
On Behalf of the Board of Directors,
Timothy Ko, CEO
For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
For media inquiries, please contact Crystal Quast at:
Telephone: +1 (647) 529-6364
Cautionary Note on Forward Looking Information
This news release contains forward‐looking statements and forward‐looking
information within the meaning of applicable securities laws. These statements
relate to future events or future performance. All statements other than
statements of historical fact may be forward‐looking statements or
information. More particularly and without limitation, this news release
contains forward‐looking statements and information relating to the engagement
and advisory services of Nancy Maher as “Special Advisor”, and other matters.
The forward‐looking statements and information are based on certain key
expectations and assumptions made by management of the Company. Although
management of the Company believes that the expectations and assumptions on
which such forward-looking statements and information are based are
reasonable, undue reliance should not be placed on the forward‐looking
statements and information since no assurance can be given that they will
prove to be correct.
Forward-looking statements and information are provided for the purpose of
providing information about the current expectations and plans of management
of the Company relating to the future. Readers are cautioned that reliance on
such statements and information may not be appropriate for other purposes,
such as making investment decisions. Since forward‐looking statements and
information address future events and conditions, by their very nature they
involve inherent risks and uncertainties. Actual results could differ
materially from those currently anticipated due to a number of factors and
risks. These include, but are not limited to, the Company’s ability to raise
further capital and the Company’s ability to obtain regulatory and exchange
approvals. Accordingly, readers should not place undue reliance on the
forward‐looking statements and information contained in this news release.
Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward‐looking statements and information contained in this news release
are made as of the date hereof and no undertaking is given to update publicly
or revise any forward‐looking statements or information, whether as a result
of new information, future events or otherwise, unless so required by
applicable securities laws. The forward-looking statements or information
contained in this news release are expressly qualified by this cautionary
Neither the CSE nor the Investment Industry Regulatory Organization of Canada
accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
(c) Copyright Newsfile Corp. 2021